Racial and ethnic minorities are reported to have higher mortality related to hepatocellular carcinoma (HCC) than non-Hispanic whites. However, it is not clear whether differences in tumor characteristics or liver dysfunction among racial or ethnic groups affect characterization of causes for this disparity. We aimed to characterize racial and ethnic differences in HCC presentation, treatment, and survival.
H epatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide and a leading cause of morbidity and mortality in patients with cirrhosis. 1 Because of the current epidemic of advanced hepatitis C virus (HCV) infection and rapidly increasing incidence of nonalcoholic steatohepatitis, HCC incidence in the United States has doubled over the past 2 decades and is predicted to continue to increase over the next 20 years. 2 HCC disproportionally affects racial/ethnic minority populations in the United States, with higher age-specific rates among non-Hispanic black (black), Hispanic, and respectively), compared with whites (2.4 per 100,000). 3 Hispanics have experienced the largest increase in HCC incidence among all racial/ethnic groups, with an estimated 4.7% increase in incidence each year since 2000 (vs 4.3% in blacks and whites and 0.6% in Asians). 3, 4 Racial and ethnic minority patients in the United States are also at risk for poor cancer-related outcomes. Racial and ethnic disparities in breast, colorectal, and cervical cancer process and outcome measures persist across the cancer care continuum, from screening underuse, to diagnostic delays, inadequate receipt or delays in treatment, and worse overall survival. [5] [6] [7] [8] Socioeconomic disadvantage, lack of health insurance, and language barriers limit access to cancer screening and treatment. [9] [10] [11] However, some believe differences in prognosis extend beyond screening process disparities and could be related to biologic differences in tumor behavior.
In HCC, prior studies have suggested racial and ethnic-specific disparities in incidence, tumor characteristics, treatment receipt, and outcomes, with blacks and Hispanics having poorer survival than whites and Asians. [12] [13] [14] [15] [16] [17] Furthermore, prior studies have found that minority patients are less likely to receive HCC-directed therapy than nonminorities, including surgical resection and liver transplantation. 12, 13, 15, 18 Although lower receipt of curative therapy among minority populations is a common finding across studies, there are conflicting data on survival differences between racial and ethnic groups. 19, 20 Previous studies have been limited by the use of population-based administrative data sets that lack clinical granularity on liver disease etiology, underlying liver function, tumor burden, and patient performance status, making it difficult to determine exactly where and why disparities occur and the magnitude of their impact on patient outcomes.
Understanding and quantifying potential differences is the first step to identify intervention targets and inform strategies to reduce existing disparities. Therefore, the aim of our study was to compare HCC presentation, treatment, and survival among Hispanic, black, and non-Hispanic white patients at 2 large urban health systems in the United States.
Methods

Study Population
Using prospectively maintained HCC databases at Parkland Memorial Health and Hospital System (Parkland) and the University of Texas (UT) Southwestern Medical Center, we identified all patients diagnosed with HCC between January 2008 and July 2017. As the safetynet health system for Dallas County, Parkland serves a large population of socioeconomically disadvantaged patients with cirrhosis and HCC. Parkland patients receive HCC screening, diagnostic evaluation, and HCCdirected therapy for no or reduced cost through a financial assistance program funded by Dallas County taxes. Although liver transplantation is not available at Parkland, eligible patients without social and financial barriers can be referred to other health systems, including UT Southwestern, for transplant evaluation. As the only National Cancer Institute-designated cancer center in North Texas, UT Southwestern acts as a tertiary care referral center for patients with HCC across Texas and surrounding states. Patients at Parkland and UT Southwestern are cared for by the same set of dedicated HCC providers and cases are reviewed at a shared multidisciplinary conference. Both Parkland and UT Southwestern have clinic availability to see patients newly diagnosed with HCC within 2 weeks of referral.
We confirmed all HCC diagnoses using the American Association for the Study of Liver Disease criteria. 21 We excluded the following: (1) patients without imaging studies and for whom we could not determine tumor characteristics; (2) patients with a liver mass without characteristic imaging (arterial enhancement with delayed washout) or histologic confirmation; and (3) patients who received treatment at an outside institution before presentation at one of the study sites. The Institutional Review Board of the UT Southwestern Medical Center approved this study.
Data Collection
We reviewed each patient's electronic medical record (EMR) to obtain patient demographics, clinical history, laboratory data, and imaging results at the time of the HCC diagnosis. Race/ethnicity was obtained by selfreport from all patients at the time of the clinic visits What You Need to Know Background Racial and ethnic minority patients with hepatocellular carcinoma may receive less curative treatment and have higher mortality than non-Hispanic whites, however, prior data are conflicting on the magnitude and factors underlying these disparities.
Findings
Black patients had significantly higher mortality and Hispanic patients had lower mortality compared with white patients after adjusting for tumor stage, liver function, receipt of HCC treatment, and insurance status.
Implications for patient care
Understanding racial/ethnic differences in hepatocellular carcinoma surveillance, treatment, and mortality is the necessary first step to allow for identification of potential intervention targets to improve patient outcomes and reduce existing disparities. 
Statistical Analysis
The Fisher exact test and the chi-square test were used to compare characteristics of the study population by race/ethnicity. Multivariable logistic regression models were used to evaluate the association between race/ ethnicity and early tumor detection, defined as BCLC stage 0 or A, and curative treatment receipt. We estimated the median overall survival, stratified by race/ethnicity, using Kaplan-Meier analysis. The overall survival was calculated from HCC diagnosis to the last known date of followup evaluation, liver transplantation, death, or the end of the study period (July 1, 2017). Log-rank tests were used to compare survival distributions by race/ethnicity. We used univariate and multivariable Cox proportional hazard regression models to identify factors associated with overall survival, adjusting for clustering by health system. We included BCLC stage and receipt of curative treatment as a priori correlates of overall survival. Other covariates were included in the multivariable model if they were associated significantly with overall survival in univariate analysis. We report adjusted associations of covariates and overall survival as hazard ratios (HRs) and 95% CIs. All tests were 2-sided and performed at the 5% significance level. Statistical analysis was performed using Stata 14.0 (College Station, TX).
Results
Patient Characteristics
We identified 1117 eligible HCC patients, of whom 401 (35.9%) were white, 384 (34.4%) were black, and 332 (29.7%) were Hispanic. Eighty-three patients of other races were excluded from analyses. Baseline patient characteristics are detailed in Table 1 . Blacks were significantly younger than whites (P ¼ .003), but age was not significantly different between Hispanics and whites (P ¼ .67). Compared with whites, blacks were more likely to have viral hepatitis (P < .001), whereas Hispanics were more likely to have alcohol-or nonalcoholic steatohepatitisrelated cirrhosis (P < .001). Similarly, obesity (body mass index, !30) was more common in Hispanics (P ¼ .02) but not blacks (P ¼ .25) compared with whites; however, both blacks (P < .001) and Hispanics (P ¼ .001) were more likely to have any component of the metabolic syndrome compared with whites. The degree of liver dysfunction significantly differed by race/ethnicity, with Child A cirrhosis less likely in Hispanics (P ¼ .003) and more likely in blacks (P ¼ .03) than whites. Specifically, blacks had less ascites and hepatic encephalopathy than whites. Performance status did not differ significantly between blacks or Hispanics compared with whites.
Clinical Presentation and Tumor Stage
One third (30.7%) of patients received care at the tertiary care health system, with Hispanics and blacks more likely than whites to be seen at the safety-net system. HCC was detected via surveillance in 40.7% of patients, incidentally in 36.5%, and symptomatically in 22.8% of patients. Despite a higher proportion of whites receiving hepatology care in the year before HCC diagnosis compared with non-whites (P ¼ .003), the proportion of HCCs detected by surveillance was similar among groups.
Differences in tumor characteristics, by race/ ethnicity, are detailed in Table 2 . There was no difference in the number of nodules between groups, including similar proportions of unifocal HCC; however, blacks were noted to have larger overall tumor burden than whites, including higher proportions of infiltrative HCC, vascular invasion, and distant metastases. Overall, only 44.0% of patients were diagnosed with HCC within Milan criteria. Compared with whites, blacks were significantly less likely to be detected within Milan criteria (P ¼ .005). Hispanics also were less likely than whites to be found within Milan criteria, but this difference did not reach statistical significance (P ¼ .11).
There 
Overall Survival
The median overall survival for all patients was 13.8 months, with 1-year and 3-year survival rates of 53.0% (Table 3) , black-white disparities in survival were most notable for BCLC stages A and D, but less pronounced for BCLC stages B and C. Survival was similar between Hispanics and whites across all BCLC stages. The association between black race and survival was mitigated but still statistically significant when adjusting for insurance status, Child-Pugh class, BCLC tumor stage, and type of HCC-directed treatment (HR, 1.12; 95% CI, 1.10-1.14) (Table 4) . When adjusting for insurance status, Child-Pugh class, BCLC tumor stage, and type of HCC-directed treatment, there was a significant 
Discussion
In this study, we used clinically granular data from a comprehensive EMR to compare HCC presentation and outcomes by race/ethnicity at 2 large US hospital systems. We found that Hispanics and blacks were less likely to be diagnosed with early stage HCC compared with whites. Both blacks and Hispanics also were less likely than whites to receive curative treatment for HCC, including among patients with early stage HCC. Although Hispanics had shorter absolute survival than whites, they had improved survival and stage-adjusted survival after adjusting for insurance coverage, Child-Pugh class, BCLC tumor stage, and receipt of HCC treatment. In contrast, blacks had significantly worse survival than whites, which persisted after adjusting for these factors.
As with most malignancies, HCC tumor burden at diagnosis impacts both prognosis and treatment decisions. HCC most commonly occurs in the background of cirrhosis; therefore, prognosis and treatment options depend on the degree of underlying liver dysfunction at presentation. A higher proportion of Hispanics and blacks were diagnosed at a later BCLC stage, however, this appears to be driven by different factors. Compared with whites, Hispanics had a decreased tumor burden but more advanced liver dysfunction, whereas blacks had better liver function but were detected more often symptomatically with a larger tumor stage. This difference in initial presentation suggests that potential targets for interventions to improve prognosis in these 2 groups may differ. Disparities in tumor stage at presentation may be owing in part to racial/ethnic differences in liver disease etiology and recognition of cirrhosis, HCC surveillance utilization, and access to primary and subspecialty health care. [22] [23] [24] [25] Differences in survival likely involve a combination of medical, financial, and social factors. Some studies have hypothesized that this difference may be related to biologic differences in tumor behavior, whereas others have highlighted sociodemographic inequalities across the HCC cancer care continuum. 24, 26, 27 Provider-level factors such as poor physician-patient communication and inherent provider biases, in addition to system-level factors such as care coordination, available technology, and treatment delays also may play a role. 28, 29 Although a prior Veterans Affairs study found that race/ethnicity was not associated with all-cause mortality in HCC, this may be attributable to system-level differences between the Veterans Affairs and the health systems evaluated in our study. 20 In our study, we found that differences in survival were mitigated after adjusting for BCLC tumor stage and receipt of HCC treatment, suggesting that these factors may explain differences in prognosis and be appropriate intervention targets for studies to reduce racial disparities in HCC prognosis. Underuse of HCC surveillance is one of the main reasons for late-stage tumor detection in the United States, with fewer than 20% of at-risk patients receiving consistent semi-annual HCC surveillance. 24 Although prior studies have suggested lower HCC surveillance in racial/ethnic minorities and persons of low socioeconomic status, 23 less than half of the patients in each racial/ethnic group in our study received HCC surveillance in the year before HCC diagnosis. Similarly, less than one third of patients in our study received curative treatment, including less than two thirds of patients with BCLC stage 0/A HCC, with lower rates in blacks and Hispanics than whites. Other studies have shown the underuse of HCC treatments, with less than 25% of US patients receiving curative treatment in clinical practice. 27 Furthermore, it has been shown that patients at safety-net hospitals are less likely to receive HCC treatment even when diagnosed at an early stage. 30 As observed in other studies, blacks and Hispanics in our study had less access to liver transplantation than whites (1.8% and 6.9% vs 10.7%, respectively), likely related in part to a lower proportion of minority patients having insurance coverage. 31 Further studies are needed to explore reasons for late-stage tumor detection and underuse of curative treatment, particularly among racial/ethnic minorities, to inform future intervention strategies. [32] [33] [34] Historically, research on existing disparities in HCC has centered on the use of large, administrative databases including Medicare and the Surveillance, Epidemiology and End Results registries. However, these large data sets have several important limitations, of particular importance in HCC compared with other cancers. They have limited clinical data regarding liver dysfunction and performance status; nonspecific tumor staging categorized as localized, regional, or distant; only capture the first HCC-directed treatment; are prone to ascertainment bias because HCC is diagnosed based on imaging criteria and not histologically in most cases; and poor capture of race/ethnicity. Although our study addressed many of these issues, it had some notable limitations. Our study's retrospective nature resulted in the potential for missing data, unmeasured cofounders, and measurement bias (eg, Eastern Cooperative Oncology Group performance status). Second, our findings may not be generalizable to other care settings, although safety-net health systems care for a disproportionate share of racial/ethnic minority patients in the United States. 30 For example, both health systems included a multidisciplinary tumor clinic, which has been shown to improve HCC-related outcomes but may not be universally available in all health care systems. 32 Furthermore, underinsured or uninsured patients at Parkland are eligible for HCC surveillance and treatment at low or no cost using a patient assistance program that is not widely available in the United States. In addition, although some patients at Parkland are referred for liver transplantation at outside institutions, the referrals are not recorded consistently in the EMR and therefore were not included in our analysis. Third, our conclusions must be interpreted in light of the inherent complexity of racial and ethnic health disparities. Race/ethnicity in both health systems was selfreported and may not be collected reliably or account for multiethnic individuals who often are forced into a single category. Self-reported race/ethnicity may differ from genetic determination, with some studies showing equal heterogeneity within races as between races. 35 Race and socioeconomic status also often are highly correlated, complicating interpretation of any observed disparities. 36 Finally, Hispanic patients represented a heterogeneous group of patients; in our study, Hispanic patients were primarily of Mexican descent and thus our findings may not be generalizable to other Hispanic populations. Overall, we believe our study's limitations are outweighed by its strengths, including its large, wellcharacterized cohort and its racially and socioeconomically diverse population.
In summary, we found differences in HCC presentation and outcomes between racial/ethnic groups. Both blacks and Hispanics were less likely to be diagnosed with early stage HCC and undergo curative treatment than whites, even among those with early stage HCC. Blacks and Hispanics both had worse absolute survival than whites, but these racial and ethnic disparities in survival were reduced, if not eliminated, after adjusting for tumor stage and receipt of HCC treatment. Our data suggest that interventions to improve early tumor detection and curative treatment receipt likely would improve HCC outcomes and reduce disparities. Our findings have important implications for health policy and highlight the need for further study on racial-ethnic disparities in HCC including the identification of additional actionable intervention targets to reduce disparities in prognosis.
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